HCW Biologics presented its lead T-Cell Engager candidate, HCW11-018b, at the 41st Society for Immunotherapy of Cancer meeting, highlighting its unique ability to convert immunologically "cold" tumors into "hot" ones by promoting immune cell infiltration and tertiary lymphoid structure formation. This multivalent molecule targets solid tumors by combining T-cell activation with immunosuppression reduction, showing promising preclinical results including tumor shrinkage and metastasis reduction. The company received FDA guidance for IND submission and plans to start first-in-human trials in early 2027, supported by ongoing GMP manufacturing preparations.
HCW Biologics' lead T-Cell Engager candidate is highlighted here with Pluang's health sector market context as of Nov 06, 2026 20:42 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 51 rose and 94 fell today. Notable movers include Amphastar Pharmaceuticals Inc (AMPH) at USD 29.45, up 6.47% with a typical hold time of 18 days; Cassava Sciences Inc (FLNA) at USD 0.48, up 6.21% with 79% buy order activity and a typical hold time of 39 days; and Erasca Inc. (ERAS) at USD 13.77, up 3.77% with a typical hold time of 4 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
